Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093457 | 0.81 | PARP1 (0.32) | PARP1 | |
| SCHEMBL7670280 | 0.81 | PARP1 (0.32) | PARP1 | |
| SCHEMBL12186852 | 0.81 | MAP4K4 (0.35) | PDPK1MAP4K4 | |
| SCHEMBL16146754 | 0.80 | GDA (0.39) | PDPK1ADORA3ADORA2A | |
| SCHEMBL4430662 | 0.79 | XDH (0.39) | PDPK1XDHYTHDC1PDE4APDE4B | |
| SCHEMBL11876693 | 0.79 | XDH (0.39) | PDPK1XDHYTHDC1PDE4APDE4B | |
| SCHEMBL12186860 | 0.78 | JAK2 (0.36) | TNNI3K | |
| SCHEMBL19778929 | 0.78 | — | — | |
| SCHEMBL12186858 | 0.78 | JAK2 (0.36) | TNNI3K | |
| SCHEMBL15354437 | 0.78 | JAK2 (0.36) | TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| WO-2023000708-A1 | POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2023-01-26 | — | — | WO | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | PDPK1 3/4885XDH 2748/4885YTHDC1 4687/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885XDH 3131/4885YTHDC1 4770/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PDPK1 30/4885XDH 2930/4885YTHDC1 4621/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885XDH 253/4885YTHDC1 4697/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | PDPK1 120/4885XDH 1155/4885YTHDC1 3871/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885XDH 3131/4885YTHDC1 4770/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885XDH 3131/4885YTHDC1 4770/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | PDPK1 19/4885XDH 1703/4885YTHDC1 4765/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | PDPK1 10/4885XDH 2726/4885YTHDC1 4770/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PDPK1 30/4885XDH 2930/4885YTHDC1 4621/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885XDH 3131/4885YTHDC1 4770/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PDPK1 30/4885XDH 2930/4885YTHDC1 4621/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | PDPK1 50/4885XDH 1489/4885YTHDC1 4533/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PDPK1 65/4885XDH 2527/4885YTHDC1 4656/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PDPK1 30/4885XDH 2930/4885YTHDC1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.